Johnson & Johnson (NYSE:JNJ) reported fiscal Q2 adjusted earnings of $2.80 per diluted share, up from $2.59 a year earlier.
Analysts polled by Capital IQ expected $2.62.
Sales for the quarter ended July 2 were $25.53 billion, up from $24.02 billion a year earlier.
Analysts surveyed by Capital IQ expected $24.67 billion.
Johnson & Johnson (NYSE:JNJ) said it now expects fiscal 2023 adjusted earnings of $10.70 to $10.80 per diluted share, compared with its prior guidance of $10.60 to $10.70 per diluted share. Analysts polled by Capital IQ are looking for $10.65.
Sales for the fiscal year are now projected to be $98.8 billion to $99.8 billion, compared with $97.9 billion to $98.9 billion previously, the company said. Analysts surveyed by Capital IQ are expecting $98.91 billion.